Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that Capstan management will participate in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference, being held between September 4-6, 2024 at the New York Marriott Marquis, New York, NY. Capstan will be hosting one-on-one meetings with investors.
About Capstan Therapeutic, Inc. (www.capstantx.com)
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827106565/en/
Contacts
Investors:
Miguel Arcinas
Senior Vice President of Corporate Development
Capstan Therapeutics
marcinas@capstantx.com
Media:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com
